Route of

administration, General action Client’s Nursing

Name of drugs dosage and Mechanism of Indication/ response to med. responsibilities
(generic and frequency of action Purpose With actual side prior to,
brand name) administration effects (if any) during, and
after
administration
Generic Name: 15 mg IVP q80 Potent anti-ulcer Short-term There are no Before:
Ranitidine drug that treatment of actual side effects
competitively and active duodenal reported but -Always check
Brand Name: reversibly ulcer; others may the dose and
Zantac inhibits histamine maintenance experience the expiry
action at H2- therapy for following adverse date before
Drug receptor sites on duodenal ulcer reaction: giving to patient
Classification: parietal cells, patient after
Gastrointestinal thus blocking healing of CNS:Headache, -Check Patient’s
agent; gastric acid acute ulcer; malaise, medical Record
antisecretory secretion. treatment of dizziness, if the patient is
(h2-receptor Indirectly reduces gastroesophage somnolence, contraindicated
antagonist) pepsin secretion al reflux insomnia, to the
but appears to disease; short- vertigo, mental medication
have minimal term treatment confusion,
effect on fasting of active, agitation, -Observe the 12
and postprandial benign gastric depression, rights of drug
serum gastrin ulcer; treatment hallucinations in administration
concentrations or of pathologic older adults.
secretion of GI -Inform the
gastric intrinsic hypersecretory CV:Bradycardia patient and
factor or mucus. conditions (with rapid IV the guardian
(e.g., Zollinger- push). that the
THERAPUETIC Ellison medication
effects: syndrome, GI:Constipation, may cause
systemic nausea, drowsiness,
Blocks daytime mastocytosis, abdominal pain, dizziness, or
and nocturnal and diarrhea. fatigue
basal gastric acid postoperative
secretion hypersecretion) Skin:Rash. During:
stimulated by ; heartburn.
histamine and -Administer
Hematologic:Re
reduces gastric the medicine
versible decrease
acid release in slowly
in WBC count,
response to food, thrombocytopeni
pentagastrin, and After:
a.
insulin. Shown to
inhibit 50% of -Monitor for
the stimulated adverse
gastric acid reactions.
secretion.